A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In this study, we discover and ch...
Main Authors: | Ejemel, M, Li, Q, Hou, S, Schiller, ZA, Tree, JA, Wallace, A, Amcheslavsky, A, Kurt Yilmaz, N, Buttigieg, KR, Elmore, MJ, Godwin, K, Coombes, N, Toomey, JR, Schneider, R, Ramchetty, AS, Close, BJ, Chen, D-Y, Conway, HL, Saeed, M, Ganesa, C, Carroll, MW, Cavacini, LA, Klempner, MS, Schiffer, CA, Wang, Y |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Nature
2020
|
Similar Items
-
Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants
by: Qi Li, et al.
Published: (2022-09-01) -
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
by: Huo, J, et al.
Published: (2020) -
IgA Vasculitis and IgA Nephropathy: Same Disease?
by: Evangeline Pillebout
Published: (2021-05-01) -
Increased Urinary IgA in Paediatric IgA Vasculitis Nephritis
by: Julien Marro, et al.
Published: (2022-11-01) -
Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy
by: Yoshihito Nihei, et al.
Published: (2023-04-01)